• Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis.

• The Phase 2 Dose-Ranging study showed clinically significant changes in increases in BMD at the spine, femoral neck, and total hip.

• Patients receiving 2.5 mg oral PTH had a placebo-adjusted increase of 3.78% in the lumbar spine (LS) BMD.

• Additionally, there was a highly statistically significant dose-dependent increase in LS BMD across all dose groups.

• Pooled 2.5 mg EB613 group had a significant placebo-adjusted 2.76% increase in the femoral neck and a 1.84% increase in total hip BMD.

• Significant decrease in serum CTX (of 21% from baseline at 6 months while P1NP was unchanged.

• The safety profile of EB613 was consistent with and similar to the known profile of injectable PTH (Forteo).

• Price Action: ENTX stock is down 1.97% at $4.49 during the market session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Medtronic Expands Recall of MiniMed 600 Series Insulin Pumps

• Biden Administration To Invest Another B In COVID-19 At-Home Tests: CNN

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.